Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

S. Sinha; M. A. Gertz; M. Q. Lacy; A. Dispenzieri; S. R. Hayman; F. K. Buadi; D. Dingli; I. N. Micallef; W. J. Hogan; D. A. Gastineau; S. V. Rajkumar; S. K. Kumar

doi:10.1038/leu.2011.308

Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

S. Sinha, M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, F. K. Buadi, D. Dingli, I. N. Micallef, W. J. Hogan, D. A. Gastineau, S. V. Rajkumar, S. K. Kumar

Hematology

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	1119-1122
Number of pages	4
Journal	Leukemia
Volume	26
Issue number	5
DOIs	https://doi.org/10.1038/leu.2011.308
State	Published - May 2012

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2011.308

Cite this

Sinha, S., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Hayman, S. R., Buadi, F. K., Dingli, D., Micallef, I. N., Hogan, W. J., Gastineau, D. A., Rajkumar, S. V., & Kumar, S. K. (2012). Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. Leukemia, 26(5), 1119-1122. https://doi.org/10.1038/leu.2011.308

Sinha, S, Gertz, MA , Lacy, MQ , Dispenzieri, A, Hayman, SR, Buadi, FK, Dingli, D , Micallef, IN , Hogan, WJ, Gastineau, DA, Rajkumar, SV & Kumar, SK 2012, 'Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies', Leukemia, vol. 26, no. 5, pp. 1119-1122. https://doi.org/10.1038/leu.2011.308

@article{0c14b03ebe8c4d9da153e9fca7c158c7,

title = "Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies",

author = "S. Sinha and Gertz, {M. A.} and Lacy, {M. Q.} and A. Dispenzieri and Hayman, {S. R.} and Buadi, {F. K.} and D. Dingli and Micallef, {I. N.} and Hogan, {W. J.} and Gastineau, {D. A.} and Rajkumar, {S. V.} and Kumar, {S. K.}",

note = "Funding Information: DRC is supported by R01CA151391-01, the Multiple Myeloma Research Foundation, and is a Sidney Kimmel Foundation Scholar. Funding Information: This study was supported in part by CA90628 (SKK) and the Hematologic Malignancies Program (Mayo Clinic). Funding Information: MAG received Honoraria from Celgene, Millenium, Neotope Eisai Inc., Lilly Research Laboratories, Optum Health Education, Research to Practice, Physician{\textquoteright}s Education Resource and Amgen Inc. MQL received research funding from Celgene. AD received research funding from Celgene and binding site. INM is on the advisory board of Genzyme. SKK received research funding from Celgene, Genzyme, Millenium, Novartis, Bayer, Merck and Cephalon and is on the advisory board of Genzyme. SS, SRH, FKB, DD, WJH, DAG and SVR declare no conflict of interest.",

year = "2012",

month = may,

doi = "10.1038/leu.2011.308",

language = "English (US)",

volume = "26",

pages = "1119--1122",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

AU - Sinha, S.

AU - Gertz, M. A.

AU - Lacy, M. Q.

AU - Dispenzieri, A.

AU - Hayman, S. R.

AU - Buadi, F. K.

AU - Dingli, D.

AU - Micallef, I. N.

AU - Hogan, W. J.

AU - Gastineau, D. A.

AU - Rajkumar, S. V.

AU - Kumar, S. K.

N1 - Funding Information: DRC is supported by R01CA151391-01, the Multiple Myeloma Research Foundation, and is a Sidney Kimmel Foundation Scholar. Funding Information: This study was supported in part by CA90628 (SKK) and the Hematologic Malignancies Program (Mayo Clinic). Funding Information: MAG received Honoraria from Celgene, Millenium, Neotope Eisai Inc., Lilly Research Laboratories, Optum Health Education, Research to Practice, Physician’s Education Resource and Amgen Inc. MQL received research funding from Celgene. AD received research funding from Celgene and binding site. INM is on the advisory board of Genzyme. SKK received research funding from Celgene, Genzyme, Millenium, Novartis, Bayer, Merck and Cephalon and is on the advisory board of Genzyme. SS, SRH, FKB, DD, WJH, DAG and SVR declare no conflict of interest.

PY - 2012/5

Y1 - 2012/5

UR - http://www.scopus.com/inward/record.url?scp=84860716728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860716728&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.308

DO - 10.1038/leu.2011.308

M3 - Letter

C2 - 22033494

AN - SCOPUS:84860716728

SN - 0887-6924

VL - 26

SP - 1119

EP - 1122

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this